Breaking News, Collaborations & Alliances

VBI, Brii Bio Partner for Hepatitis B

Brii Bio paid VBI $11 million upfront, including a $4 million upfront payment & a $7 million equity investment at $3 a share

VBI Vaccines Inc. has entered into a license and collaboration agreement with Brii Biosciences for the development of a functional cure for the treatment of chronic hepatitis B infection, using VBI’s recombinant, protein-based immuno-therapeutic, VBI-2601.  As part of the collaboration, Brii Bio paid VBI an upfront payment of $11 million, consisting of a $4 million upfront payment and a $7 million equity investment priced at $3.05 per share. VBI is also eligible to receive an additional $...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters